Developer docs
API playgroundTry for free, no card

Search company profiles

Galenica

Full company profile

uuid000ah1v

Namestring
Galenica
Legal namestring
Galenica AG
Websiteurl
galenica.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Galenica AG is Switzerland's leading fully integrated healthcare provider, operating a vertically integrated network of more than 20 Business Units that spans retail pharmacy (flagship brands Amavita, Sun Store, Coop Vitality and Winconcept, totaling 381 locations by end-2025), pharmaceutical wholesale and logistics (Galexis, Alloga, UFD, Pharmapool), mail-order and specialty pharmacy (MediService, Medifilm), IT and digital services (HCI Solutions, Aquantic), diagnostic laboratory services (Labor Team / Galenica Diagnostics), and proprietary consumer healthcare brands (Verfora, Padma, Spagyros, Cannaplant, Lifestage Solutions, Bichsel). The underlying technology stack combines physical pharmacy retail systems with a wholesale and pre-wholesale logistics backbone, e-prescription integration, same-day medicine delivery, a chronic disease management platform, and a dedicated Chief IT & Digital Business function that coordinates digital initiatives across Business Units.

The company generates revenue across six interlocking streams: retail pharmacy sales of OTC and prescription products (transaction-based, ~15% of stationary retail tied to OTC drugs), pharmaceutical wholesale distribution (margin-based transactions), mail-order and specialty pharmacy through MediService, logistics and IT services sold to third parties, diagnostic laboratory services following the September 2025 Labor Team acquisition, and sales of proprietary consumer healthcare brands. It serves a broad customer base spanning end consumers via B2C pharmacy channels, independent partner pharmacies and drugstores via wholesale, physician practices and hospitals, nursing homes and Spitex home-care organizations, pharmaceutical manufacturers, and Swiss health insurers. Distribution is omnichannel and domestically concentrated, combining owned storefronts, B2B logistics, e-commerce, and digital health services within a single Swiss operator.

Galenica AG was established in its current form in 2017 following the separation of the former Galenica Group into the listed Galenica AG (pharmacy and healthcare network) and Vifor Pharma. The company is listed on the SIX Swiss Exchange under ticker GALE (also referenced as GALNF in news coverage), is headquartered in Bern, and employs approximately 9,500 people. In FY2025 it delivered record group sales of CHF 4.14 billion (+5.5% year-over-year) with adjusted EBIT up 11.3% and an 8.7% dividend increase, while UBS projects revenue to peak at CHF 4.66 billion in FY28 before declining as anticipated Swiss OTC deregulation affects the retail franchise.

Short descriptiontext

Galenica AG operates Switzerland's largest vertically integrated pharmacy and healthcare network, combining 381 retail pharmacies (Amavita, Sun Store, Coop Vitality), wholesale logistics (Galexis, Alloga), mail-order pharmacy (MediService), IT services (HCI Solutions), and diagnostic laboratories (Labor Team) to serve Swiss patients, healthcare providers, and insurers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersBern, Switzerland
HQ citystring
Bern
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retail pharmacy network, pharmaceutical wholesale distribution, pharmacy logistics services, mail-order specialty pharmacy, healthcare IT services
Industry4 codes
1Retail & Community Pharmacies (Chain/Independent)
CodeHLAFALAAPrimaryYes
2Specialty Pharmacy & Complex Therapy Management Platforms
CodeHLACAKAGPrimaryNo
3Specialty Pharmacies (Complex/High-Cost Therapies)
CodeHLAFALACPrimaryNo
4Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops)
CodeCRAOAHAKPrimaryNo
NAICS code2 codes
  • Pharmacies and Drug Retailers456110
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Retail-Drug Stores And Proprietary Stores5912
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Retail Pharmacy and Pharmaceutical Distribution
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model6 records
1Retail pharmacy sales
TypeTransaction Fee
Description

Revenue from over-the-counter (OTC) and prescription pharmaceutical products, parapharmacy items and services sold through the company's directly operated pharmacy brands (Amavita, Sun Store, Coop Vitality and Winconcept), including online pharmacy sales and same-day delivery. Approximately 15% of stationary retail revenues are linked to OTC drugs. Transaction-based revenue at point of sale.

ad-hoc-news.de
2Wholesale pharmaceutical distribution
TypeTransaction Fee
Description

Revenue from pharmaceutical wholesale distribution to pharmacies, drugstores, medical practices, hospitals and other partners via the Galexis and Alloga logistics and wholesale arms. Margin-based transaction revenue.

ad-hoc-news.de
3Mail-order / specialty pharmacy (MediService)
TypeTransaction Fee
Description

Revenue from MediService mail-order pharmacy operations delivering medicines directly to patients at home, including specialty pharmaceutical services.

ad-hoc-news.de
4Logistics & IT services
TypeManaged Services
Description

Revenue from Logistics and IT services provided by the Galexis/Alloga logistics unit and HCI Solutions IT unit to third-party pharmacies, partners and the broader Swiss healthcare market. Mix of managed services and licensing-style arrangements.

galenica.com
5Diagnostic laboratory services
TypeProfessional Services
Description

New revenue stream from the launch of Galenica Diagnostics following the acquisition of Labor Team (Diagnostics Group GmbH), offering diagnostic laboratory services to physicians and other healthcare partners in Switzerland.

pharmiweb.com
6Products & Brands (Verfora, Padma, Spagyros, etc.)
TypeHardware Sales
Description

Revenue from proprietary consumer healthcare brands and products (e.g., Verfora, Padma, Spagyros, Cannaplant/Lifestage Solutions, UFD) sold through Galenica's pharmacy network and partner channels. Product sales plus licensing of own brands.

ad-hoc-news.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details2 tiers
1Retail pharmacy pricing (not publicly disclosed)
ModelUnit Pricing
Notes

Retail OTC and prescription pricing at Amavita, Sun Store, Coop Vitality and other Galenica pharmacies is not publicly listed. Employees benefit from a personnel discount of up to 25%.

jobs.galenica.com
2Listed equity price target CHF 86
ModelOther
Notes

UBS cut Galenica's 12-month price target to CHF 86 from CHF 85 after downgrading the stock to 'sell'; the stock price shown on the corporate site was CHF 83.85 (June 2026). Publicly disclosed only via third-party analyst coverage.

in.investing.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 6 records shown
1Amavita
Description

Flagship pharmacy retail brand within the Galenica network.

ad-hoc-news.de
+5 more records
Core offering1 text field

Galenica AG operates a vertically integrated Swiss healthcare platform combining directly operated retail pharmacies (Amavita, Sun Store, Coop Vitality, Winconcept — 381 locations), pharmaceutical wholesale and pre-wholesale logistics (Galexis, Alloga), mail-order and online pharmacy (MediService), IT and digital health services (HCI Solutions), proprietary consumer healthcare brands (Verfora, Padma, Spagyros) and diagnostic laboratory services (Galenica Diagnostics, built on the acquired Labor Team). The network serves both end consumers in Switzerland and B2B customers such as partner pharmacies, drugstores, physicians, hospitals, nursing homes, home-care organisations, pharmaceutical manufacturers and health insurers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Group sales CHF 4.14 billion in 2025, +5.5% year-over-year (record).
+4 more records
Product and service10 records
1Amavita pharmacy retail
CategoryRetail pharmacy
2Sun Store pharmacy retail
CategoryRetail pharmacy
3Coop Vitality pharmacy retail
CategoryRetail pharmacy
4Winconcept franchise partner network
CategoryRetail pharmacy franchise
5MediService mail-order and specialty pharmacy
CategoryMail-order / specialty pharmacy
6Galexis pharmaceutical wholesale
CategoryPharmaceutical wholesale
7Alloga pharmaceutical logistics and pre-wholesale
CategoryPharmaceutical logistics
8HCI Solutions healthcare IT services
CategoryHealthcare IT services
9Galenica Diagnostics laboratory services
CategoryClinical diagnostics
10Verfora consumer healthcare products
CategoryConsumer healthcare products
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagship Pharmacy Brand In The Network; Key Retail Channel Partner With Coop, The Swiss Retailer.TypeStrategic or Co-development Partner
Description

Coop Vitality operates as a Galenica Business Unit with the brand tied to Coop, the Swiss retailer, and is included in the 381-location Galenica pharmacy network. Coop Vitality AG is led within Galenica by the Chief Pharmacies Sales function, and the CEO sits on the Board of Coop Vitality AG.

Strategic tierBackground Reference Only — Historical Auditor Relationship Via Chair Of The Board, Not An Active Commercial Partnership.TypeImplementation/ SI/ Consulting Partner
Description

The Chair of Galenica's Board (Dr Markus R. Neuhaus) is a former CEO and Chair of PwC Switzerland; PwC appears only in his biography and not as a named active partner.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European pharmaceutical wholesale and pharmacy retail group (BENU, Lloyds Apotheke). Directly comparable to Galenica's Galexis wholesale arm and 381-store retail network across Switzerland and Europe.

TypeDirect peer
Description

Swiss-domiciled cross-border online pharmacy and mail-order dispenser. Direct competitor to Galenica's MediService mail-order and online pharmacy proposition, and the principal challenger UBS cites in its deregulation thesis.

TypeDirect peer
Description

European pharmaceutical distribution arm of McKesson, operating wholesale across multiple European markets. Directly comparable to Galexis/Alloga wholesale and pre-wholesale operations.

TypeDirect peer
Description

European pharmacy wholesale and retail operator (Lloyds Pharmacy in some markets). Comparable business mix across wholesale distribution and retail pharmacy footprint.

TypeEmerging player
Description

Leading European online pharmacy operating across Germany, Austria, Switzerland and other markets. Comparable to Galenica's online pharmacy, MediService mail-order and same-day delivery proposition.

TypeDirect peer
Description

European pharmaceutical wholesaler and pre-wholesaler owned by Walgreens Boots Alliance. Directly comparable to Galenica's Galexis wholesale and Alloga pre-wholesale logistics operations.

TypeBroad incumbent
Description

Large US integrated pharmacy retail, PBM and healthcare services conglomerate. Broader portfolio analog to Galenica's retail + wholesale + IT + diagnostics platform; benchmark for vertical integration economics in pharmacy.

TypeDirect peer
Description

Swiss-headquartered mail-order pharmacy business, now operating as part of Redcare Pharmacy / DocMorris. Historical direct competitor in the Swiss online and mail-order pharmacy market alongside Galenica's MediService.

TypeRegional player
Description

Swiss primary care medical and pharmacy network. Comparable regional footprint to Galenica's 381-pharmacy Swiss network and increasingly relevant as Galenica expands into diagnostics via Labor Team.

TypeDirect peer
Description

European clinical diagnostics and laboratory services provider. Comparable to Galenica's newly launched Galenica Diagnostics business unit (built around the acquired Labor Team / Diagnostics Group GmbH).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries20 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galenica

Retail Pharmacy and Pharmaceutical Distributiongalenica.com

Galenica AG operates Switzerland's largest vertically integrated pharmacy and healthcare network, combining 381 retail pharmacies (Amavita, Sun Store, Coop Vitality), wholesale logistics (Galexis, Alloga), mail-order pharmacy (MediService), IT services (HCI Solutions), and diagnostic laboratories (Labor Team) to serve Swiss patients, healthcare providers, and insurers.

What Galenica does

Galenica AG is Switzerland's leading fully integrated healthcare provider, operating a vertically integrated network of more than 20 Business Units that spans retail pharmacy (flagship brands Amavita, Sun Store, Coop Vitality and Winconcept, totaling 381 locations by end-2025), pharmaceutical wholesale and logistics (Galexis, Alloga, UFD, Pharmapool), mail-order and specialty pharmacy (MediService, Medifilm), IT and digital services (HCI Solutions, Aquantic), diagnostic laboratory services (Labor Team / Galenica Diagnostics), and proprietary consumer healthcare brands (Verfora, Padma, Spagyros, Cannaplant, Lifestage Solutions, Bichsel). The underlying technology stack combines physical pharmacy retail systems with a wholesale and pre-wholesale logistics backbone, e-prescription integration, same-day medicine delivery, a chronic disease management platform, and a dedicated Chief IT & Digital Business function that coordinates digital initiatives across Business Units.

The company generates revenue across six interlocking streams: retail pharmacy sales of OTC and prescription products (transaction-based, ~15% of stationary retail tied to OTC drugs), pharmaceutical wholesale distribution (margin-based transactions), mail-order and specialty pharmacy through MediService, logistics and IT services sold to third parties, diagnostic laboratory services following the September 2025 Labor Team acquisition, and sales of proprietary consumer healthcare brands. It serves a broad customer base spanning end consumers via B2C pharmacy channels, independent partner pharmacies and drugstores via wholesale, physician practices and hospitals, nursing homes and Spitex home-care organizations, pharmaceutical manufacturers, and Swiss health insurers. Distribution is omnichannel and domestically concentrated, combining owned storefronts, B2B logistics, e-commerce, and digital health services within a single Swiss operator.

Galenica AG was established in its current form in 2017 following the separation of the former Galenica Group into the listed Galenica AG (pharmacy and healthcare network) and Vifor Pharma. The company is listed on the SIX Swiss Exchange under ticker GALE (also referenced as GALNF in news coverage), is headquartered in Bern, and employs approximately 9,500 people. In FY2025 it delivered record group sales of CHF 4.14 billion (+5.5% year-over-year) with adjusted EBIT up 11.3% and an 8.7% dividend increase, while UBS projects revenue to peak at CHF 4.66 billion in FY28 before declining as anticipated Swiss OTC deregulation affects the retail franchise.

Galenica firmographics

Firmographics
Name
Galenica
Legal name
Galenica AG
Website
https://galenica.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Galenica AG operates Switzerland's largest vertically integrated pharmacy and healthcare network, combining 381 retail pharmacies (Amavita, Sun Store, Coop Vitality), wholesale logistics (Galexis, Alloga), mail-order pharmacy (MediService), IT services (HCI Solutions), and diagnostic laboratories (Labor Team) to serve Swiss patients, healthcare providers, and insurers.
Ownership category
akta.pro rank

Galenica industry classification

Industry
Product category
Retail Pharmacy and Pharmaceutical Distribution
NAICS
Pharmacies and Drug Retailers (456110), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Retail & Community Pharmacies (Chain/Independent) (HLAFALAA)
akta.pro secondary industries
Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)

Keywords

  • Retail pharmacy network
  • Pharmaceutical wholesale distribution
  • Pharmacy logistics services
  • Mail-order specialty pharmacy
  • Healthcare IT services

Where Galenica is headquartered

Location

Headquarters

HQ city
Bern
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Galenica business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Retail pharmacy sales: Revenue from over-the-counter (OTC) and prescription pharmaceutical products, parapharmacy items and services sold through the company's directly operated pharmacy brands (Amavita, Sun Store, Coop Vitality and Winconcept), including online pharmacy sales and same-day delivery. Approximately 15% of stationary retail revenues are linked to OTC drugs. Transaction-based revenue at point of sale.
  2. Wholesale pharmaceutical distribution: Revenue from pharmaceutical wholesale distribution to pharmacies, drugstores, medical practices, hospitals and other partners via the Galexis and Alloga logistics and wholesale arms. Margin-based transaction revenue.
  3. Mail-order / specialty pharmacy (MediService): Revenue from MediService mail-order pharmacy operations delivering medicines directly to patients at home, including specialty pharmaceutical services.
  4. Logistics & IT services: Revenue from Logistics and IT services provided by the Galexis/Alloga logistics unit and HCI Solutions IT unit to third-party pharmacies, partners and the broader Swiss healthcare market. Mix of managed services and licensing-style arrangements.
  5. Diagnostic laboratory services: New revenue stream from the launch of Galenica Diagnostics following the acquisition of Labor Team (Diagnostics Group GmbH), offering diagnostic laboratory services to physicians and other healthcare partners in Switzerland.
  6. Products & Brands (Verfora, Padma, Spagyros, etc.): Revenue from proprietary consumer healthcare brands and products (e.g., Verfora, Padma, Spagyros, Cannaplant/Lifestage Solutions, UFD) sold through Galenica's pharmacy network and partner channels. Product sales plus licensing of own brands.

Pricing tiers

ModelBillingPrice
Unit Pricing—Retail pharmacy pricing (not publicly disclosed)
Other—Listed equity price target CHF 86

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Galenica product offering

Product offering

Core offering

Galenica AG operates a vertically integrated Swiss healthcare platform combining directly operated retail pharmacies (Amavita, Sun Store, Coop Vitality, Winconcept — 381 locations), pharmaceutical wholesale and pre-wholesale logistics (Galexis, Alloga), mail-order and online pharmacy (MediService), IT and digital health services (HCI Solutions), proprietary consumer healthcare brands (Verfora, Padma, Spagyros) and diagnostic laboratory services (Galenica Diagnostics, built on the acquired Labor Team). The network serves both end consumers in Switzerland and B2B customers such as partner pharmacies, drugstores, physicians, hospitals, nursing homes, home-care organisations, pharmaceutical manufacturers and health insurers.

Differentiator

Problem solved

Functional benefit

Brands

  • Amavita: Flagship pharmacy retail brand within the Galenica network.
  • Sun Store
  • Coop Vitality
  • Galexis
  • Alloga
  • Galenica Diagnostics

Products and services

  • Amavita pharmacy retail
  • Sun Store pharmacy retail
  • Coop Vitality pharmacy retail
  • Winconcept franchise partner network
  • MediService mail-order and specialty pharmacy
  • Galexis pharmaceutical wholesale
  • Alloga pharmaceutical logistics and pre-wholesale
  • HCI Solutions healthcare IT services
  • Galenica Diagnostics laboratory services
  • Verfora consumer healthcare products

Quantifiable outcome

  • Group sales CHF 4.14 billion in 2025, +5.5% year-over-year (record).
  • +4 more outcomes

Companies that use Galenica

Customer profile

Segments8 records

Ideal customer profiles4 records

Galenica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Galenica partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship pharmacy brand in the network; key retail channel partner with coop, the swiss retailer. and background reference only — historical auditor relationship via chair of the board, not an active commercial partnership..

  • Coop (Coop Vitality AG joint venture)flagship pharmacy brand in the network; key retail channel partner with coop, the swiss retailer.Strategic or Co-development PartnerCoop Vitality operates as a Galenica Business Unit with the brand tied to Coop, the Swiss retailer, and is included in the 381-location Galenica pharmacy network. Coop Vitality AG is led within Galenica by the Chief Pharmacies Sales function, and the CEO sits on the Board of Coop Vitality AG.
  • PwC (PricewaterhouseCoopers) — external auditorbackground reference only — historical auditor relationship via chair of the board, not an active commercial partnership.Implementation/ SI/ Consulting PartnerThe Chair of Galenica's Board (Dr Markus R. Neuhaus) is a former CEO and Chair of PwC Switzerland; PwC appears only in his biography and not as a named active partner.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Galenica competitors and assessment

Company assessment

Direct peers

  • PHOENIX Group: European pharmaceutical wholesale and pharmacy retail group (BENU, Lloyds Apotheke). Directly comparable to Galenica's Galexis wholesale arm and 381-store retail network across Switzerland and Europe.
  • DocMorris (Redcare Pharmacy): Swiss-domiciled cross-border online pharmacy and mail-order dispenser. Direct competitor to Galenica's MediService mail-order and online pharmacy proposition, and the principal challenger UBS cites in its deregulation thesis.
  • McKesson Europe: European pharmaceutical distribution arm of McKesson, operating wholesale across multiple European markets. Directly comparable to Galexis/Alloga wholesale and pre-wholesale operations.
  • Celesio (McKesson): European pharmacy wholesale and retail operator (Lloyds Pharmacy in some markets). Comparable business mix across wholesale distribution and retail pharmacy footprint.
  • Alliance Healthcare (Walgreens Boots Alliance): European pharmaceutical wholesaler and pre-wholesaler owned by Walgreens Boots Alliance. Directly comparable to Galenica's Galexis wholesale and Alloga pre-wholesale logistics operations.
  • Zur Rose Group: Swiss-headquartered mail-order pharmacy business, now operating as part of Redcare Pharmacy / DocMorris. Historical direct competitor in the Swiss online and mail-order pharmacy market alongside Galenica's MediService.
  • Synlab: European clinical diagnostics and laboratory services provider. Comparable to Galenica's newly launched Galenica Diagnostics business unit (built around the acquired Labor Team / Diagnostics Group GmbH).

Emerging players

  • Shop Apotheke Europe: Leading European online pharmacy operating across Germany, Austria, Switzerland and other markets. Comparable to Galenica's online pharmacy, MediService mail-order and same-day delivery proposition.

Broad incumbents

  • CVS Health: Large US integrated pharmacy retail, PBM and healthcare services conglomerate. Broader portfolio analog to Galenica's retail + wholesale + IT + diagnostics platform; benchmark for vertical integration economics in pharmacy.

Regional players

  • Medbase: Swiss primary care medical and pharmacy network. Comparable regional footprint to Galenica's 381-pharmacy Swiss network and increasingly relevant as Galenica expands into diagnostics via Labor Team.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Galenica social profiles

Digital presence

Galenica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galenica leadership team

Management profile

Number of profiles

Profiles12 records

Galenica subsidiaries and ownership

Company hierarchy

Subsidiaries20 records

Galenica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galenica M&A and investment

M&A and investment

M&A6 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galenica

What does Galenica do?

Galenica AG operates a vertically integrated Swiss healthcare platform combining directly operated retail pharmacies (Amavita, Sun Store, Coop Vitality, Winconcept — 381 locations), pharmaceutical wholesale and pre-wholesale logistics (Galexis, Alloga), mail-order and online pharmacy (MediService), IT and digital health services (HCI Solutions), proprietary consumer healthcare brands (Verfora, Padma, Spagyros) and diagnostic laboratory services (Galenica Diagnostics, built on the acquired Labor Team). The network serves both end consumers in Switzerland and B2B customers such as partner pharmacies, drugstores, physicians, hospitals, nursing homes, home-care organisations, pharmaceutical manufacturers and health insurers.

Is Galenica a public or private company?

Galenica is a public company. It is classified as public and is currently operating.

When was Galenica founded?

Galenica was founded in 2017. It employs 5,001 to 10,000 people.

Where is Galenica based?

Galenica is headquartered in Bern, Switzerland, in the Europe region.

How does Galenica make money?

Six revenue lines are on record. Retail pharmacy sales are the primary driver. The others are wholesale pharmaceutical distribution, mail-order / specialty pharmacy (MediService), logistics & IT services, diagnostic laboratory services and products & Brands (Verfora, Padma, Spagyros, etc.).

Who are Galenica's main competitors?

Direct peers on record are PHOENIX Group, DocMorris (Redcare Pharmacy), McKesson Europe, Celesio (McKesson), Alliance Healthcare (Walgreens Boots Alliance), Zur Rose Group and Synlab. Shop Apotheke Europe is listed as an emerging player. CVS Health is listed as a broad incumbent. Medbase is listed as a regional player.

Does Galenica have an API?

No public API is recorded for Galenica.

What industry is Galenica in?

Galenica's product category is Retail Pharmacy and Pharmaceutical Distribution. Its primary akta.pro industry code is HLAFALAA, Retail & Community Pharmacies (Chain/Independent), with a secondary code of HLACAKAG, Specialty Pharmacy & Complex Therapy Management Platforms. Its NAICS code is 456110 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StGalenica (SWX:GALE) Stock Hints At Strength Despite Softer Profit ConversionGalenica reported H1 2026 revenue of CHF2.143 billion, a 7% increase from the prior year, driven by organic growth and the acquisition of Labor Team. However, net income excluding extra items fell approximately 24% to CHF66.8 million due to restructuring costs and lower product sales, despite an improvement in the adjusted EBIT margin for its Products & Care segment.Seeking AlphaGalenica AG (GALNF) Q2 2026 Earnings Call TranscriptGalenica AG is hosting a conference call to discuss its first-half 2026 financial results and strategic updates. The presentation features remarks from CEO Marc Werner on strategy implementation, followed by an analysis of the company's figures for the period.YahooGalenica Ltd (WBO:GALE) (H1 2026) Earnings Call Highlights: Strong Core Growth and Strategic ...Galenica Ltd reported strong H1 2026 results with 7.1% sales growth reaching CHF2.136 billion and 7.1% adjusted EBIT growth of just under CHF118 million, with adjusted EBIT up 12.6% excluding one-off items. The company is gaining market share in prescription medicines with local pharmacies growing 6.2% and outperforming the market, while the integration of LaborTeam contributed 3.1% to sales growth. Management reaffirmed its 2026 guidance and medium-term targets citing good momentum for the second half, despite headwinds including a flat Swiss OTC market, temporary inventory setbacks in international business, and upcoming regulatory changes affecting lab tests and home care nutrition reimbursement.Seeking AlphaGalenica AG 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:GALNF) 2026-08-06Galenica AG published its Q2 2026 financial results in an earnings call. The article includes a presentation of the company's quarterly performance.MarketScreenerGalenica: Soft H1 26 profitability, but guidance reiteratedGalenica AG reported a soft first half in 2026 regarding profitability while reiterating its guidance for the year. The company operates in the healthcare sector in Switzerland and manages a network of pharmacies and product distribution. Despite the challenges, Galenica continues its partnerships with several business entities for product marketing and distribution.FinanzNachrichten.deGalenica wächst im Halbjahr profitabel - Home Care und Diagnostik legen kräftig zuThe Swiss healthcare company Galenica AG reported a 7% increase in revenue to 2.14 billion CHF and a 7% rise in adjusted EBIT to 117.7 million CHF for the first half of 2026. On a basis adjusted for one-time effects from the prior year, the operating result grew even stronger at 13%. The company confirmed its full-year outlook for 2026.FinanzNachrichten.deAdhoc: Galenica AG: Galenica wächst mit hoher Kontinuität weiterGalenica AG continued its growth trajectory in the first half of 2026, reporting a 7.1% increase in revenue to CHF 2,136.5 million and a 7.1% rise in adjusted EBIT to CHF 117.7 million. The diversified Swiss healthcare network confirmed its full-year 2026 outlook, expecting revenue growth of 5-7% and EBIT growth of 6-8%, with Home Care and Diagnostics emerging as key growth drivers. The company expanded its pharmacy network by a net 3 outlets to 384 locations, while demand for paid consulting services rose 27% to 193,000 units including 25,000 vaccinations.Seeking AlphaGalenica AG (GALNF) Q4 2025 Earnings Call TranscriptGalenica AG reported strong 2025 full-year results with sales growth of 5.5%, EBIT rising 11.3% to CHF 234.8 million, and adjusted net profit increasing 3% to CHF 189 million. The company announced the acquisition of Labor Team in September 2025 and plans to close the pharmaceutical production division of its Bichsel subsidiary in the first half of 2026, while maintaining a positive outlook with 2026 guidance of 5-7% sales growth and 6-8% EBIT growth. For the mid-term, Galenica targets EBIT of CHF 270 million by 2027, driven by expected efficiency gains from its ongoing ERP system changeover in logistics.Investing.comEarnings call transcript: Galenica Group’s strong 2025 performance boosts investor confidence By Investing.comGalenica Group reported strong 2025 financial results with consolidated sales growth of 5.5% and EBIT increasing by 11.3% to CHF 243.8 million, driven by growth in both its Logistics and IT and Products and Care segments. The company's acquisition of Labor Team in September 2025 contributed approximately 1% to group sales growth and marked a strategic expansion into the diagnostics market. For 2026, Galenica projects sales growth of 5%-7% and adjusted EBIT growth of 6%-8%, while also announcing plans to close Bichsel's pharmaceutical production division.Investing.comGalenica raises dividend 8.7%, lifts medium-term EBIT target after 2025 beat By Investing.comSwiss healthcare group Galenica proposed an 8.7% dividend increase to CHF 2.50 per share after reporting an 11.3% rise in full-year 2025 adjusted earnings to CHF 234.8 million, beating analyst consensus of CHF 234 million. The company raised its medium-term adjusted EBIT target for 2027 to CHF 270 million from CHF 250 million, partly reflecting the September 2025 acquisition of diagnostic laboratory group Labor Team, with the Logistics and IT segment delivering standout 14.8% EBIT growth. For 2026, Galenica forecasts sales growth of 5-7% and adjusted EBIT growth of 6-8%, with costs related to the planned closure of Bichsel's production division concentrated in the first half of the year.